Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study.

ABSTRACT:

Background

Lifelong antiplatelet treatment is recommended after ischaemic vascular events, on the basis of trials done mainly in patients younger than 75 years. Upper gastrointestinal bleeding is a serious complication, but had low case fatality in trials of aspirin and is not generally thought to cause long-term disability. Consequently, although co-prescription of proton-pump inhibitors (PPIs) reduces upper gastrointestinal bleeds by 70-90%, uptake is low and guidelines are conflicting. We aimed to assess the risk, time course, and outcomes of bleeding on antiplatelet treatment for secondary prevention in patients of all ages.

Methods

We did a prospective population-based cohort study in patients with a first transient ischaemic attack, ischaemic stroke, or myocardial infa

SUBMITTER: Li L 

PROVIDER: S-EPMC5537194 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature